{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-330599","form_type":"8-K","ticker":"CATX","cik":"0000728387","company_name":"Perspective Therapeutics, Inc.","filed_at":"2026-08-03T20:15:24+00:00","discovered_at":"2026-08-03T20:17:01.644490+00:00","generated_at":"2026-08-03T20:17:52.767568+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"confidence":"low","headline":"Perspective Therapeutics updates corporate presentation highlighting 212Pb pipeline","bullets":["Updated presentation includes ASCO 2026 data for VMT-α-NET in neuroendocrine tumors with 68 patients treated.","VMT01 for melanoma shows preliminary anti-tumor activity at 3.0 mCi dose in ongoing Phase 1/2a.","PSV359 targeting FAP-α for solid tumors is in Phase 1/2a with improved tumor retention.","Company emphasizes 212Pb-based theranostic approach and direct-to-hospital delivery model."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-330599","json":"https://secwatch.observer/filing/0001193125-26-330599.json","markdown":"https://secwatch.observer/filing/0001193125-26-330599.md","text":"https://secwatch.observer/filing/0001193125-26-330599.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/728387/000119312526330599/0001193125-26-330599-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/728387/000119312526330599/catx-20260803.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-03T20:17:52.767568+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}